Angiotensin Receptor Blockers (ARBs) Market Report 2026

Angiotensin Receptor Blockers (ARBs) Market Overview

• Angiotensin Receptor Blockers (ARBs) market size has reached to $8.78 billion in 2025 • Expected to grow to $11.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Rising Cardiovascular Disease Incidence Sparks Surge In Angiotensin Receptor Blockers Market • Market Trend: Innovative Product Solution In The Angiotensin Receptor Blockers Market • North America was the largest region in 2025.

What Is Covered Under Angiotensin Receptor Blockers (ARBs) Market?

Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder. The main products of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan and olmesartan. Losartan is an angiotensin receptor blocker that lowers the risk of stroke while treating hypertension and diabetic nephropathy. Their various applications include hypertension, cardiovascular diseases, kidney diseases, and others for use by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

What Is The Angiotensin Receptor Blockers (ARBs) Market Growth Forecast?

The angiotensin receptor blockers (arbs) market size is expected to see steady growth in the next few years. It will grow to $11.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to aging population, growing demand for personalized medicine, technological advancements in drug delivery systems, increase in healthcare expenditure, expansion of specialty clinics. Major trends in the forecast period include personalized hypertension management, growth in chronic kidney disease treatments, expansion of cardiovascular disease therapies, increasing adoption of oral arb formulations, rise in hospital & specialty clinic prescriptions.

What Are The Drivers Of The Angiotensin Receptor Blockers (ARBs) Market?

The increasing incidence of cardiovascular diseases is expected to propel the growth of the angiotensin receptor blockers market going forward. Cardiovascular disease (CVD) is any condition affecting the heart or blood vessels. It is frequently associated with the development of fatty deposits within the arteries (atherosclerosis) and an increased risk of blood clots. Angiotensin receptor blockers lower blood pressure and improve the heart's capacity to pump blood by helping in vein and artery relaxation, which can minimize the risk of cardiovascular disease. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024 up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market. The increase in the prevalence of hypertension diseases is expected to propel the growth of the angiotensin receptor blockers (ARBs) market going forward. Hypertension, often known as high or rising blood pressure, is a disorder characterized by chronically elevated blood vessel pressure. Angiotensin receptor blockers (ARBs) are a type of medication that is commonly used to treat hypertension. They primarily function by relaxing and widening the blood arteries, giving the blood greater room to pass through. Thus, increasing hypertension diseases among people will increase the demand for angiotensin receptor blockers. For instance, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, published that approximately 1.28 billion adults aged 30 to 79 globally have hypertension, with the majority (two-thirds) residing in low- and middle-income countries. It is estimated that 46% of adults with hypertension are unaware of their condition. Therefore, the increase in the prevalence of hypertension diseases is driving the growth of the angiotensin receptor blockers (ARBs) industry.

Key Players In The Global Angiotensin Receptor Blockers (ARBs) Market

Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.

Global Angiotensin Receptor Blockers (ARBs) Market Trends and Insights

Major companies in the angiotensin receptor blocker market are developing advanced products, such as angiotensin receptor neprilysin inhibitors, to enhance treatment options and improve outcomes for patients with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) are a class of medications used to treat heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched sacubitril + valsartan tablets, which specialize in the treatment of heart failure, specifically targeting heart failure with reduced ejection fraction (HFrEF). This combination falls under the class of medications known as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril enhances the natriuretic peptide (NP) system, which alleviates fluid overload and promotes blood vessel dilation, while valsartan blocks the renin-angiotensin system (RAS) to lower blood pressure and lessens the heart's workload. Together, they effectively improve heart failure symptoms, reduce the risk of cardiovascular mortality, and decrease the chances of hospitalization due to heart failure. They are marketed under the brand name Sacu V.

What Defines the Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Angiotensin Receptor Blockers (ARBs) Market Report 2026?

The angiotensin receptor blockers (arbs) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (arbs) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.